Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment
Main Authors: | , , , , , , , |
---|---|
格式: | Conference item |
语言: | English |
出版: |
BMJ Publishing Group
2022
|